Checkpoint immunitario (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Checkpoint immunitario" in Italian language version.

refsWebsite

Global rank Italian rank

30nih.gov

4^th place

9^th place

29doi.org

2^nd place

7^th place

10oadoi.org

799^th place

22^nd place

4web.archive.org

1^st place

1bloomberg.com

99^th place

274^th place

1astrazeneca.com

low place

1tgtherapeutics.com

low place

1immuno-oncologynews.com

low place

1macrogenics.com

low place

1incyte.com

low place

1aimac.it

low place

1economist.com

254^th place

402^nd place

aimac.it (Global: low place; Italian: low place)

Scheda AIMAC su Nivolumab https://www.aimac.it/farmaci-tumore/anticorpi-monoclonali/nivolumab-opdivo

astrazeneca.com (Global: low place; Italian: low place)

(EN) Image and broadcast library - AstraZeneca, su astrazeneca.com. URL consultato il 29 gennaio 2018.

bloomberg.com (Global: 99^th place; Italian: 274^th place)

Angela Zimm, Cancer ‘Miracle’ Patients Studied Anew for Disease Clues, in Bloomberg, 12 aprile 2014. URL consultato il 25 giugno 2015.

doi.org (Global: 2^nd place; Italian: 7^th place)

dx.doi.org

Hendriks J, Gravestein LA, Tesselaar K, van Lier RA, Schumacher TN e Borst J., CD27 is required for generation and long-term maintenance of T cell immunity, in Nat Immunol, vol. 1, n. 5, 1º novembre 2000, pp. 433-40, DOI:10.1038/80877, PMID 11062504.
Borst J, Hendriks J, Xiao Y, CD27 and CD70 in T cell and B cell activation, in Curr Opin Immunol, vol. 17, n. 3, 1º giugno 2005, pp. 275-81, DOI:10.1016/j.coi.2005.04.004, PMID 15886117.
Coquet JM, Middendorp S, van der Horst G, Kind J, Veraar EA, Xiao Y, Jacobs H, Borst J, The CD27 and CD70 costimulatory pathway inhibits effector function of T helper 17 cells and attenuates associated autoimmunity, in Immunity, vol. 38, n. 1, 24 gennaio 2013, pp. 53-65, DOI:10.1016/j.immuni.2012.09.009, PMID 23159439.
He LZ, Prostak N, Thomas LJ, Vitale L, Weidlick J, Crocker A, Pilsmaker CD, Round SM, Tutt A, Glennie MJ, Marsh H, Keler T, Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice, in J Immunol, vol. 191, n. 8, 15 ottobre 2013, pp. 4174-83, DOI:10.4049/jimmunol.1300409, PMID 24026078.
O'Sullivan B, Thomas R, CD40 and dendritic cell function, in Crit Rev Immunol, vol. 23, n. 1, 1º gennaio 2003, pp. 83-107, DOI:10.1615/critrevimmunol.v23.i12.50, PMID 12906261.
Michael Croft, Takanori So e Wei Duan, The significance of OX40 and OX40L to T-cell biology and immune disease, in Immunological Reviews, vol. 229, n. 1, maggio 2009, pp. 173-191, DOI:10.1111/j.1600-065X.2009.00766.x, PMID 19426222. URL consultato il 29 gennaio 2018.
Andrew D. Weinberg, Nicholas P. Morris e Magdalena Kovacsovics-Bankowski, Science gone translational: the OX40 agonist story, in Immunological Reviews, vol. 244, n. 1, novembre 2011, pp. 218-231, DOI:10.1111/j.1600-065X.2011.01069.x, PMID 22017441. URL consultato il 29 gennaio 2018.
Brendan D. Curti, Magdalena Kovacsovics-Bankowski e Nicholas Morris, OX40 is a potent immune-stimulating target in late-stage cancer patients, in Cancer Research, vol. 73, n. 24, 15 dicembre 2013, pp. 7189-7198, DOI:10.1158/0008-5472.CAN-12-4174. URL consultato il 29 gennaio 2018.
Simona Ronchetti, Ornella Zollo e Stefano Bruscoli, GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations, in European Journal of Immunology, vol. 34, n. 3, marzo 2004, pp. 613-622, DOI:10.1002/eji.200324804. URL consultato il 29 gennaio 2018.
Giuseppe Nocentini, Simona Ronchetti e Salvatore Cuzzocrea, GITR/GITRL: more than an effector T cell co-stimulatory system, in European Journal of Immunology, vol. 37, n. 5, maggio 2007, pp. 1165-1169, DOI:10.1002/eji.200636933. URL consultato il 29 gennaio 2018.
David A. Schaer, Sadna Budhu e Cailian Liu, GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability, in Cancer Immunology Research, vol. 1, n. 5, novembre 2013, pp. 320-331, DOI:10.1158/2326-6066.CIR-13-0086. URL consultato il 29 gennaio 2018.
Eastwood D, Findlay L, Poole S, Bird C, Wadhwa M, Moore M, Burns C, Thorpe R, Stebbings R, Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells, in Br J Pharmacol, vol. 161, n. 3, 1º ottobre 2010, pp. 512-526, DOI:10.1111/j.1476-5381.2010.00922.x, PMC 2990151, PMID 20880392.
Onur Boyman e Jonathan Sprent, The role of interleukin-2 during homeostasis and activation of the immune system, in Nature Reviews. Immunology, vol. 12, n. 3, 17 febbraio 2012, pp. 180-190, DOI:10.1038/nri3156. URL consultato il 29 gennaio 2018.
Robert D. Leone, Ying-Chun Lo e Jonathan D. Powell, A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy, in Computational and Structural Biotechnology Journal, vol. 13, 2015, pp. 265-272, DOI:10.1016/j.csbj.2015.03.008. URL consultato il 29 gennaio 2018.
A. I. Chapoval, J. Ni e J. S. Lau, B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production, in Nature Immunology, vol. 2, n. 3, marzo 2001, pp. 269-274, DOI:10.1038/85339. URL consultato il 29 gennaio 2018.
Judith Leitner, Christoph Klauser e Winfried F. Pickl, B7-H3 is a potent inhibitor of human T-cell activation: No evidence for B7-H3 and TREML2 interaction, in European Journal of Immunology, vol. 39, n. 7, luglio 2009, pp. 1754-1764, DOI:10.1002/eji.200839028. URL consultato il 29 gennaio 2018.
Yixiang Mao, Wei Li e Kai Chen, B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer, in Oncotarget, vol. 6, n. 5, 20 febbraio 2015, pp. 3452-3461, DOI:10.18632/oncotarget.3097. URL consultato il 29 gennaio 2018.
Denarda Dangaj, Evripidis Lanitis e Aizhi Zhao, Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses, in Cancer Research, vol. 73, n. 15, 1º agosto 2013, pp. 4820-4829, DOI:10.1158/0008-5472.CAN-12-3457. URL consultato il 29 gennaio 2018.
Laurent Derré, Jean-Paul Rivals e Camilla Jandus, BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination, in The Journal of Clinical Investigation, vol. 120, n. 1, gennaio 2010, pp. 157-167, DOI:10.1172/JCI40070. URL consultato il 29 gennaio 2018.
Paula Kolar, Karin Knieke e J. Kolja E. Hegel, CTLA-4 (CD152) controls homeostasis and suppressive capacity of regulatory T cells in mice, in Arthritis and Rheumatism, vol. 60, n. 1, gennaio 2009, pp. 123-132, DOI:10.1002/art.24181. URL consultato il 29 gennaio 2018.
(EN) Nicholas L Syn, Michele W L Teng, Tony S K Mok e Ross A Soo, De-novo and acquired resistance to immune checkpoint targeting, in The Lancet Oncology, vol. 18, n. 12, pp. e731–e741, DOI:10.1016/s1470-2045(17)30607-1.
George C. Prendergast, Courtney Smith e Sunil Thomas, Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer, in Cancer Immunology, Immunotherapy: CII, vol. 63, n. 7, luglio 2014, pp. 721-735, DOI:10.1007/s00262-014-1549-4. URL consultato il 29 gennaio 2018.
Grosso JF, Kelleher CC, Harris TJ, Maris CH, Hipkiss EL, De Marzo A, Anders R, Netto G, Getnet D, Bruno TC, Goldberg MV, Pardoll DM, Drake CG, LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems, in J Clin Invest, vol. 117, n. 11, 1º novembre 2007, pp. 3383-92, DOI:10.1172/jci31184, PMC 2000807, PMID 17932562.
Philips GK, Atkins M, Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies, in Int Immunol, vol. 27, n. 1, 1º gennaio 2015, pp. 39-46, DOI:10.1093/intimm/dxu095, PMID 25323844.
Hastings WD, Anderson DE, Kassam N, Koguchi K, Greenfield EA, Kent SC, Zheng XX, Strom TB, Hafler DA, Kuchroo VK, TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines, in Eur J Immunol, vol. 39, n. 9, 1º settembre 2009, pp. 2492-501, DOI:10.1002/eji.200939274, PMC 2759376, PMID 19676072.
Zhu C, Anderson AC, Kuchroo VK, TIM-3 and its regulatory role in immune responses, in Curr Top Microbiol Immunol, vol. 350, 11 agosto 2010, pp. 1-15, DOI:10.1007/82_2010_84, PMID 20700701.
Wang L, Rubinstein R, Lines JL, Wasiuk A, Ahonen C, Guo Y, Lu LF, Gondek D, Wang Y, Fava RA, Fiser A, Almo S, Noelle RJ, VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses, in J Exp Med, vol. 208, n. 3, 14 marzo 2011, pp. 577-92, DOI:10.1084/jem.20100619, PMC 3058578, PMID 21383057.
Lines JL, Pantazi E, Mak J, Sempere LF, Wang L, O'Connell S, Ceeraz S, Suriawinata AA, Yan S, Ernstoff MS, Noelle R, VISTA is an immune checkpoint molecule for human T cells, in Cancer Res, vol. 74, n. 7, 1º aprile 2014, pp. 1924-32, DOI:10.1158/0008-5472.CAN-13-1504, PMC 3979527, PMID 24691993.
Drew M. Pardoll, The blockade of immune checkpoints in cancer immunotherapy, in Nature Reviews Cancer, vol. 12, n. 4, 22 marzo 2012, pp. 252-264, DOI:10.1038/nrc3239, PMC 4856023, PMID 22437870.

economist.com (Global: 254^th place; Italian: 402^nd place)

Cancer drugs are getting better and dearer, su The Economist. URL consultato il 19 maggio 2017.

immuno-oncologynews.com (Global: low place; Italian: low place)

Immunotherapy, NKTR-214, Shows Activity Against Solid Tumors in Clinical Trial, su immuno-oncologynews.com.

incyte.com (Global: low place; Italian: low place)

investor.incyte.com

Incyte - This is Pivotal Science^{[collegamento interrotto]}, su Incyte - This is Pivotal Science. URL consultato il 29 gennaio 2018.

macrogenics.com (Global: low place; Italian: low place)

ir.macrogenics.com

(EN) MacroGenics Provides Update on Corporate Progress and First Quarter 2015 Financial Results (NASDAQ:MGNX), su ir.macrogenics.com. URL consultato il 29 gennaio 2018.

nih.gov (Global: 4^th place; Italian: 9^th place)

ncbi.nlm.nih.gov

Hendriks J, Gravestein LA, Tesselaar K, van Lier RA, Schumacher TN e Borst J., CD27 is required for generation and long-term maintenance of T cell immunity, in Nat Immunol, vol. 1, n. 5, 1º novembre 2000, pp. 433-40, DOI:10.1038/80877, PMID 11062504.
Agematsu K, Memory B cells and CD27, in Histology and Histopathology, vol. 15, n. 2, 1º aprile 2000, pp. 573-6, PMID 10809378.
Borst J, Hendriks J, Xiao Y, CD27 and CD70 in T cell and B cell activation, in Curr Opin Immunol, vol. 17, n. 3, 1º giugno 2005, pp. 275-81, DOI:10.1016/j.coi.2005.04.004, PMID 15886117.
Coquet JM, Middendorp S, van der Horst G, Kind J, Veraar EA, Xiao Y, Jacobs H, Borst J, The CD27 and CD70 costimulatory pathway inhibits effector function of T helper 17 cells and attenuates associated autoimmunity, in Immunity, vol. 38, n. 1, 24 gennaio 2013, pp. 53-65, DOI:10.1016/j.immuni.2012.09.009, PMID 23159439.
He LZ, Prostak N, Thomas LJ, Vitale L, Weidlick J, Crocker A, Pilsmaker CD, Round SM, Tutt A, Glennie MJ, Marsh H, Keler T, Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice, in J Immunol, vol. 191, n. 8, 15 ottobre 2013, pp. 4174-83, DOI:10.4049/jimmunol.1300409, PMID 24026078.
O'Sullivan B, Thomas R, CD40 and dendritic cell function, in Crit Rev Immunol, vol. 23, n. 1, 1º gennaio 2003, pp. 83-107, DOI:10.1615/critrevimmunol.v23.i12.50, PMID 12906261.
Michael Croft, Takanori So e Wei Duan, The significance of OX40 and OX40L to T-cell biology and immune disease, in Immunological Reviews, vol. 229, n. 1, maggio 2009, pp. 173-191, DOI:10.1111/j.1600-065X.2009.00766.x, PMID 19426222. URL consultato il 29 gennaio 2018.
Andrew D. Weinberg, Nicholas P. Morris e Magdalena Kovacsovics-Bankowski, Science gone translational: the OX40 agonist story, in Immunological Reviews, vol. 244, n. 1, novembre 2011, pp. 218-231, DOI:10.1111/j.1600-065X.2011.01069.x, PMID 22017441. URL consultato il 29 gennaio 2018.
Brendan D. Curti, Magdalena Kovacsovics-Bankowski e Nicholas Morris, OX40 is a potent immune-stimulating target in late-stage cancer patients, in Cancer Research, vol. 73, n. 24, 15 dicembre 2013, pp. 7189-7198, DOI:10.1158/0008-5472.CAN-12-4174. URL consultato il 29 gennaio 2018.
Simona Ronchetti, Ornella Zollo e Stefano Bruscoli, GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations, in European Journal of Immunology, vol. 34, n. 3, marzo 2004, pp. 613-622, DOI:10.1002/eji.200324804. URL consultato il 29 gennaio 2018.
Giuseppe Nocentini, Simona Ronchetti e Salvatore Cuzzocrea, GITR/GITRL: more than an effector T cell co-stimulatory system, in European Journal of Immunology, vol. 37, n. 5, maggio 2007, pp. 1165-1169, DOI:10.1002/eji.200636933. URL consultato il 29 gennaio 2018.
David A. Schaer, Sadna Budhu e Cailian Liu, GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability, in Cancer Immunology Research, vol. 1, n. 5, novembre 2013, pp. 320-331, DOI:10.1158/2326-6066.CIR-13-0086. URL consultato il 29 gennaio 2018.
Yvonne Burmeister, Timo Lischke e Anja C. Dahler, ICOS controls the pool size of effector-memory and regulatory T cells, in Journal of Immunology (Baltimore, Md.: 1950), vol. 180, n. 2, 15 gennaio 2008, pp. 774-782. URL consultato il 29 gennaio 2018.
Eastwood D, Findlay L, Poole S, Bird C, Wadhwa M, Moore M, Burns C, Thorpe R, Stebbings R, Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells, in Br J Pharmacol, vol. 161, n. 3, 1º ottobre 2010, pp. 512-526, DOI:10.1111/j.1476-5381.2010.00922.x, PMC 2990151, PMID 20880392.
Onur Boyman e Jonathan Sprent, The role of interleukin-2 during homeostasis and activation of the immune system, in Nature Reviews. Immunology, vol. 12, n. 3, 17 febbraio 2012, pp. 180-190, DOI:10.1038/nri3156. URL consultato il 29 gennaio 2018.
Robert D. Leone, Ying-Chun Lo e Jonathan D. Powell, A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy, in Computational and Structural Biotechnology Journal, vol. 13, 2015, pp. 265-272, DOI:10.1016/j.csbj.2015.03.008. URL consultato il 29 gennaio 2018.
A. I. Chapoval, J. Ni e J. S. Lau, B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production, in Nature Immunology, vol. 2, n. 3, marzo 2001, pp. 269-274, DOI:10.1038/85339. URL consultato il 29 gennaio 2018.
Judith Leitner, Christoph Klauser e Winfried F. Pickl, B7-H3 is a potent inhibitor of human T-cell activation: No evidence for B7-H3 and TREML2 interaction, in European Journal of Immunology, vol. 39, n. 7, luglio 2009, pp. 1754-1764, DOI:10.1002/eji.200839028. URL consultato il 29 gennaio 2018.
Yixiang Mao, Wei Li e Kai Chen, B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer, in Oncotarget, vol. 6, n. 5, 20 febbraio 2015, pp. 3452-3461, DOI:10.18632/oncotarget.3097. URL consultato il 29 gennaio 2018.
Denarda Dangaj, Evripidis Lanitis e Aizhi Zhao, Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses, in Cancer Research, vol. 73, n. 15, 1º agosto 2013, pp. 4820-4829, DOI:10.1158/0008-5472.CAN-12-3457. URL consultato il 29 gennaio 2018.
Laurent Derré, Jean-Paul Rivals e Camilla Jandus, BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination, in The Journal of Clinical Investigation, vol. 120, n. 1, gennaio 2010, pp. 157-167, DOI:10.1172/JCI40070. URL consultato il 29 gennaio 2018.
Paula Kolar, Karin Knieke e J. Kolja E. Hegel, CTLA-4 (CD152) controls homeostasis and suppressive capacity of regulatory T cells in mice, in Arthritis and Rheumatism, vol. 60, n. 1, gennaio 2009, pp. 123-132, DOI:10.1002/art.24181. URL consultato il 29 gennaio 2018.
George C. Prendergast, Courtney Smith e Sunil Thomas, Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer, in Cancer Immunology, Immunotherapy: CII, vol. 63, n. 7, luglio 2014, pp. 721-735, DOI:10.1007/s00262-014-1549-4. URL consultato il 29 gennaio 2018.
Grosso JF, Kelleher CC, Harris TJ, Maris CH, Hipkiss EL, De Marzo A, Anders R, Netto G, Getnet D, Bruno TC, Goldberg MV, Pardoll DM, Drake CG, LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems, in J Clin Invest, vol. 117, n. 11, 1º novembre 2007, pp. 3383-92, DOI:10.1172/jci31184, PMC 2000807, PMID 17932562.
Philips GK, Atkins M, Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies, in Int Immunol, vol. 27, n. 1, 1º gennaio 2015, pp. 39-46, DOI:10.1093/intimm/dxu095, PMID 25323844.
Hastings WD, Anderson DE, Kassam N, Koguchi K, Greenfield EA, Kent SC, Zheng XX, Strom TB, Hafler DA, Kuchroo VK, TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines, in Eur J Immunol, vol. 39, n. 9, 1º settembre 2009, pp. 2492-501, DOI:10.1002/eji.200939274, PMC 2759376, PMID 19676072.
Zhu C, Anderson AC, Kuchroo VK, TIM-3 and its regulatory role in immune responses, in Curr Top Microbiol Immunol, vol. 350, 11 agosto 2010, pp. 1-15, DOI:10.1007/82_2010_84, PMID 20700701.
Wang L, Rubinstein R, Lines JL, Wasiuk A, Ahonen C, Guo Y, Lu LF, Gondek D, Wang Y, Fava RA, Fiser A, Almo S, Noelle RJ, VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses, in J Exp Med, vol. 208, n. 3, 14 marzo 2011, pp. 577-92, DOI:10.1084/jem.20100619, PMC 3058578, PMID 21383057.
Lines JL, Pantazi E, Mak J, Sempere LF, Wang L, O'Connell S, Ceeraz S, Suriawinata AA, Yan S, Ernstoff MS, Noelle R, VISTA is an immune checkpoint molecule for human T cells, in Cancer Res, vol. 74, n. 7, 1º aprile 2014, pp. 1924-32, DOI:10.1158/0008-5472.CAN-13-1504, PMC 3979527, PMID 24691993.
Drew M. Pardoll, The blockade of immune checkpoints in cancer immunotherapy, in Nature Reviews Cancer, vol. 12, n. 4, 22 marzo 2012, pp. 252-264, DOI:10.1038/nrc3239, PMC 4856023, PMID 22437870.

oadoi.org (Global: 799^th place; Italian: 22^nd place)

Hendriks J, Gravestein LA, Tesselaar K, van Lier RA, Schumacher TN e Borst J., CD27 is required for generation and long-term maintenance of T cell immunity, in Nat Immunol, vol. 1, n. 5, 1º novembre 2000, pp. 433-40, DOI:10.1038/80877, PMID 11062504.
Borst J, Hendriks J, Xiao Y, CD27 and CD70 in T cell and B cell activation, in Curr Opin Immunol, vol. 17, n. 3, 1º giugno 2005, pp. 275-81, DOI:10.1016/j.coi.2005.04.004, PMID 15886117.
Coquet JM, Middendorp S, van der Horst G, Kind J, Veraar EA, Xiao Y, Jacobs H, Borst J, The CD27 and CD70 costimulatory pathway inhibits effector function of T helper 17 cells and attenuates associated autoimmunity, in Immunity, vol. 38, n. 1, 24 gennaio 2013, pp. 53-65, DOI:10.1016/j.immuni.2012.09.009, PMID 23159439.
He LZ, Prostak N, Thomas LJ, Vitale L, Weidlick J, Crocker A, Pilsmaker CD, Round SM, Tutt A, Glennie MJ, Marsh H, Keler T, Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice, in J Immunol, vol. 191, n. 8, 15 ottobre 2013, pp. 4174-83, DOI:10.4049/jimmunol.1300409, PMID 24026078.
O'Sullivan B, Thomas R, CD40 and dendritic cell function, in Crit Rev Immunol, vol. 23, n. 1, 1º gennaio 2003, pp. 83-107, DOI:10.1615/critrevimmunol.v23.i12.50, PMID 12906261.
Michael Croft, Takanori So e Wei Duan, The significance of OX40 and OX40L to T-cell biology and immune disease, in Immunological Reviews, vol. 229, n. 1, maggio 2009, pp. 173-191, DOI:10.1111/j.1600-065X.2009.00766.x, PMID 19426222. URL consultato il 29 gennaio 2018.
Andrew D. Weinberg, Nicholas P. Morris e Magdalena Kovacsovics-Bankowski, Science gone translational: the OX40 agonist story, in Immunological Reviews, vol. 244, n. 1, novembre 2011, pp. 218-231, DOI:10.1111/j.1600-065X.2011.01069.x, PMID 22017441. URL consultato il 29 gennaio 2018.
(EN) Nicholas L Syn, Michele W L Teng, Tony S K Mok e Ross A Soo, De-novo and acquired resistance to immune checkpoint targeting, in The Lancet Oncology, vol. 18, n. 12, pp. e731–e741, DOI:10.1016/s1470-2045(17)30607-1.
Philips GK, Atkins M, Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies, in Int Immunol, vol. 27, n. 1, 1º gennaio 2015, pp. 39-46, DOI:10.1093/intimm/dxu095, PMID 25323844.
Zhu C, Anderson AC, Kuchroo VK, TIM-3 and its regulatory role in immune responses, in Curr Top Microbiol Immunol, vol. 350, 11 agosto 2010, pp. 1-15, DOI:10.1007/82_2010_84, PMID 20700701.

tgtherapeutics.com (Global: low place; Italian: low place)

ir.tgtherapeutics.com

(EN) TG Therapeutics Enters Into a Global Collaboration With Checkpoint Therapeutics to Develop and Commercialize Novel Immuno-Oncology Targeted Antibodies (OTC:TGTX), su ir.tgtherapeutics.com. URL consultato il 29 gennaio 2018.

web.archive.org (Global: 1^st place; Italian: 1^st place)

CDX-1127 – Monoclonal Antibody Targeting CD27, su celldex.com, Celldex Therapeutics. URL consultato il 19 gennaio 2018 (archiviato dall'url originale il 3 ottobre 2018).
(EN) Pieris Pharmaceuticals to Present Data on Novel Anti-CD137 and HER2 Bispecific Immuno-Oncology Program at UBS Global Healthcare Conference :: Pieris Pharmaceuticals, Inc. (PIRS), su pieris.com. URL consultato il 29 gennaio 2018 (archiviato dall'url originale il 3 ottobre 2018).
(EN) Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine (NASDAQ:NKTR), su ir.nektar.com. URL consultato il 29 gennaio 2018 (archiviato dall'url originale il 19 dicembre 2017).
Copia archiviata, su newlinkgenetics.com. URL consultato il 19 gennaio 2018 (archiviato dall'url originale il 4 novembre 2015).

Checkpoint immunitario (Italian Wikipedia)

aimac.it (Global: low place; Italian: low place)

astrazeneca.com (Global: low place; Italian: low place)

bloomberg.com (Global: 99th place; Italian: 274th place)

doi.org (Global: 2nd place; Italian: 7th place)

dx.doi.org

economist.com (Global: 254th place; Italian: 402nd place)

immuno-oncologynews.com (Global: low place; Italian: low place)

incyte.com (Global: low place; Italian: low place)

investor.incyte.com

macrogenics.com (Global: low place; Italian: low place)

ir.macrogenics.com

nih.gov (Global: 4th place; Italian: 9th place)

ncbi.nlm.nih.gov

oadoi.org (Global: 799th place; Italian: 22nd place)

tgtherapeutics.com (Global: low place; Italian: low place)

ir.tgtherapeutics.com

web.archive.org (Global: 1st place; Italian: 1st place)

bloomberg.com (Global: 99^th place; Italian: 274^th place)

doi.org (Global: 2^nd place; Italian: 7^th place)

economist.com (Global: 254^th place; Italian: 402^nd place)

nih.gov (Global: 4^th place; Italian: 9^th place)

oadoi.org (Global: 799^th place; Italian: 22^nd place)

web.archive.org (Global: 1^st place; Italian: 1^st place)